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Hepatitis C virus (HCV) has a propensity to cause chronic infection, with a low proportion of patients exhibiting a sustained
response to interferon-a (IFNa) therapy. An earlier report suggested that HCV inhibits IFNa-induced signal transduction
through the Jak/Stat pathway by preventing the formation of the transacting factor ISGF3 complex, although the effect on
downstream pathway and the specific viral protein responsible for inhibition of IFNa-mediated signal transduction were not
elucidated. HCV core protein displays a number of intriguing functional properties and has been implicated in virus-mediated
pathogenesis. In this study, we have analyzed the effect of core protein upon IFNa- or IFNg-induced regulation of the Jak/Stat
signaling pathway. HCV core protein expression exhibited a reduced Stat1 expression in IFN-treated mammalian cells. A gel
retardation assay suggested a reduced level of formation of the transacting factors, GAF and ISGF3, in IFN-treated cells.
Further studies from protein expression and RNase protection assay revealed that the reduced level of GAF or ISGF3
formation could be attributed to modulation of Stat1 protein expression, an important player for innate immunity in host
defense mechanism. However, these modulatory effects did not interfere with the activation of the downstream effector
genes, IRF-1 and 561, in IFN-treated cells. Stable transfectants of cells after introduction of a plasmid DNA encoding both the
structural and the nonstructural proteins of HCV also exhibited a similar effect. Taken together, these results suggest that
although expression of the core protein alone or with other HCV proteins modulate transacting factors of Jak/Stat signaling
pathway, expression of the downstream effector genes IRF-1 and 561 remains unaffected upon IFN treatment and may
contribute to host defense mechanism. © 2001 Academic Press
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Hepatitis C virus (HCV) often causes a prolonged and
persistent infection in humans. The most important fea-
ture of persistent HCV infection is the development of
chronic hepatitis in half of the infected individuals, and
the potential for disease progression to hepatocellular
carcinoma (Saito et al., 1990; DiBisceglie et al., 1998;
Hayashi et al., 1999; Jeffers, 2000). This has been attrib-
uted in part to the effect of viral gene product(s) on the
expression of host cellular genes. Unfortunately, a num-
ber of important issues related to HCV persistence and
disease progression are unknown at this time. Further-
more, neither a vaccine nor any other means of an
effective chemotherapy is available to eradicate HCV
infection. HCV genotypes 1a and 1b are predominant in
patients with chronic hepatitis C in the United States
(Zein et al., 1996), and interferon-a (IFNa) alone or in
ombination with ribavirin is the current available ther-
py (Martin et al., 1998). However, a significant number of
ases do not respond well to therapeutic treatment, and
1 To whom correspondence and reprint requests should be ad-
ressed at Division of Infectious Diseases and Immunology, Saintm
t
ouis University, 3635 Vista Avenue, St. Louis, MO 63110. Fax: (314)
71-3816. E-mail: rayr@slu.edu.
379he reason is not clear (Moradpur and Blum, 1999;
uidotti and Chishari, 2000).
Signal transducers and activators of transcription
STATs) have drawn considerable attention due to their
nique mode of action, and diversity of biological effects,
hich include the ability to control an immune response
nd an antiviral effect and to participate in cell transfor-
ation (Ihle, 1996; O’Shea, 1997). IFNa and IFNg bind to
heir respective cell surface receptors and activate dis-
inct but related signal transduction pathways, culminat-
ng in the activation of an overlapping set of interferon-
ensitive genes (ISGs). Upon binding of IFNa/b to recep-
tors, their associated protein kinases (Jak1 and Tyk2)
phosphorylate Y701 of Stat1 and Y690 of Stat2. Stat1 and
Stat2 then heterodimerize, translocate to the nucleus,
and associate with p48 to form ISG factor 3 (ISGF3).
ISGF3 activates the transcription of genes containing
IFN-stimulated response elements (ISREs) within their
promoters. The full activity of Stat1 also depends upon
the phosphorylation of S727 via the mitogen-activated
protein kinase pathway. On the other hand, IFNg upon
inding to specific receptors will similarly phosphorylate
701 of Stat1 through their associated protein tyrosine
inases (Jak1 and Jak2). Phosphorylated Stat1 ho-
odimerizes to form g-activated factor (GAF), which ac-
ivates the transcription of genes containing g-activated
0042-6822/01 $35.00
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380 BASU ET AL.sequence (GAS) elements within their promoters. Phos-
phorylation of Stat1 on S727 is also required for the full
activity of GAF (Darnell et al., 1994; Stark et al., 1998).
MHC class II expression is controlled predominantly
at the level of transcription (Boss, 1997). IFNa/b and
IFNg has been shown to enhance the expression of
HC class I and MHC class II molecules (Taniguchi et
l., 2001). The expression of MHC class II molecules is
lso uniquely regulated by IRF-1, via an indirect mecha-
ism. The expression of CIITA, a critical transcription
actor for MHC class II gene induction by IFNg, requires
tat1 and IRF-1 (Muhlethaler-Mottet et al., 1998;
Piskurich et al., 1999). IFNg can induce transcription of
genes through many different cis elements (Leonard and
en, 1996; Muhlethaler-Mottet et al., 1998). GAS has
been found in the regulatory regions of the high-affinity
IgG receptor gene, the IRF-1 gene, and the Ly-6A/E gene.
The GAS element is both necessary and sufficient to
confer transcriptional activation of IRF-1 gene by IFNg.
The genomic region encoding the HCV core protein is
ocated between amino acids 1 and 191 and is likely to
e the first gene product synthesized in virus-infected
ells due to its localization at the 59 end of the HCV
olyprotein transcript. In addition to its ability to interact
ith the viral genomic region to form nucleocapsids
Shimoike et al., 1999), the presence of a putative DNA-
inding motif, nuclear localization signals, phosphoryla-
ion sites, and a nucleocytoplasmic localization of the
ore protein suggest its possible function as a gene
egulatory protein (Shih et al., 1993). A role for HCV core
rotein in the transcriptional regulation of cellular pro-
oters has been observed (Kim et al., 1994; Ray et al.,
995, 1997, 1998b; Chang et al., 1998; Shrivastava et al.,
998; Lu et al., 1999; Ray et al., 2000; Otsuka et al., 2000;
Bergqvist and Rice, 2001). In the course of these studies
on transcriptional regulation, we have analyzed a num-
ber of core protein-associated functional properties, in-
cluding the regulation of apoptotic cell death and the
promotion of cell growth (Ray et al., 1996a,b, 1998a, 1997,
2000). While all of these functions may be important in
ensuring the survival of HCV in the human host, the
precise mechanism of core protein-mediated functions
has yet to be delineated.
An earlier report using an inducible system expressing
the entire HCV open reading frame in human osteosar-
coma cells suggested that HCV inhibits IFNa-induced
signal transduction through the Jak/Stat pathway by pre-
venting the formation of the transacting factor ISGF3
complex (Heim et al., 1999). However, the specific viral
protein responsible for an inhibition of IFNa-mediated
signal transduction and the effect on downstream path-
way was not examined. In this study, we have investi-
gated whether the expression of HCV core protein alone
and together with other HCV proteins may modulate the
cytokine-inducible gene expression of the Jak/Stat signal
transduction pathway in IFNa- or IFNg-treated cells. Our
a
Gresults suggest that expression of HCV protein(s) mod-
ulates the formation of the GAF and ISGF3 complexes
but does not interfere with the IFN-stimulated activation
of the downstream IRF-1 or 561 gene.
RESULTS
Effect of HCV protein on Stat1 expression in IFN-
treated cells
Interferon treatment of cells causes immediate activa-
tion of the transacting factor GAF and ISGF3. Once acti-
vated they translocate from cytoplasm to nucleus, bind to
the ISRE or GAS element of IFN inducible genes, and
activate their transcription. Since Stat1 is a component of
both the activation factors GAF and ISGF3 complex, the
distribution of Stat1 was investigated by an indirect im-
munofluorescence using mock transfected control, or
stable transfectants of HeLa cells expressing core pro-
tein alone or together with other HCV proteins in un-
treated and IFN-treated cells. Additionally, stable trans-
fectants of HeLa cells expressing CD4 antigen (HeLaT4)
was included in this experiment to verify the effect of an
unrelated ectotopic protein expression upon transloca-
tion of Stat1 following IFN treatment. Untreated cells
exhibited a weak intracellular localization of the Stat1
protein (Figs. 1a, 1d, 1g, and 1j). However, a bright nu-
clear fluorescence of Stat1 was observed upon treat-
ment of control HeLa or HeLa T4 cells with IFNa or IFNg
(Figs. 1b, 1c, 1k, and 1l). In contrast, a diffuse and pre-
dominantly perinuclear localization of Stat1 was ob-
served in IFN-treated HeLa cells expressing core protein
alone or together with other HCV proteins (Figs. 1e, 1f,
1h, and 1i). IFNa or IFNg treatment of HCV protein
expressing HT1080 or HepG2 cells exhibited a relatively
weak nuclear translocation of Stat1 when compared to
the mock transfected control (data not shown). Thus,
HCV core protein is probably modulating the Jak/Stat
pathway at a stage prior to GAF or ISGF3 activation.
HCV core protein expression reduces the level of
IFN-induced GAF and ISGF3 transacting factors
To investigate the possible role of HCV core protein in
GAF or ISGF3 activation, a gel retardation assay was
performed. IFN-treated or untreated HeLa, HepG2, and
HT1080 cells stably expressing core alone or together
with other HCV proteins were used for this purpose.
Mock transfected cells were separately used as control.
Formation of a DNA–protein complex with the mobility
and specificity of GAF was observed in both HeLa and
core expressing HeLa cells following IFNg treatment.
he image of the separation profile is shown in Fig. 2A.
he specificity of GAF complex was verified using an
nti-Stat1 antibody which disrupted the intensity of the
AF–DNA complex. While use of an anti-Stat2 antibody
p
(
her HC
IFN-tre
381HCV CORE PROTEIN AND ISGF3/GAF MODULATIONor unrelated antibody (data not shown in figure) as con-
trol did not inhibit GAF–DNA complex formation. In some
cases, addition of antibody disrupts the formation of the
complex rather than further changing its mobility (Sam-
brook and Russell, 2001). This may be due to high affinity
of the antibody to Stat1, resulting in competition of the
DNA binding sites for complex formation. Our observa-
tion of a decreased intensity of the GAF complex using
an antibody to Stat1 is similar to those reported earlier by
other investigators (Li et al., 1998, 1999). The uncharac-
terized band below GAF appeared in extracts of both
untreated and IFN-treated cells, as observed earlier
(Levy et al., 1990; Li et al., 1998). This complex was
FIG. 1. Effect of HCV protein on Stat1 expression in IFN-treated HeL
rotein alone (d, e, and f), or together with other HCV proteins (g, h, and
j, k, and i) were either left untreated (a, d, g, and j) or treated with IFN
temperature. Cells were incubated with a monoclonal antibody to S
isothiocyanate was added for cell staining. Treatment with IFNg or IFNa
cells. In contrast, cells expressing core protein alone or together with ot
in the perinuclear regions. Arrows indicate the distribution of Stat1 inspecifically inhibited by antibody to Stat1 or Stat2; how-
ever, anti-Stat2 antibody did not inhibit GAF formation.These complexes may represent inactivated heteromeric
form of the Stats and awaits further characterization.
Densitometric scanning of the autoradiogram sug-
gested that the GAF–DNA complex is ;4.8-fold higher in
mock transfected control cells as compared to the core
protein transfected HeLa cells (Figs. 2A and 2B). The
GAF–DNA complex formation was also examined in
HeLa cells stably transfected with HCV1–2962 plasmid.
Mock transfected control HeLa cells exhibited an ;2.5-
fold higher level of GAF–DNA complex formation than
HeLa cells expressing core along with other HCV pro-
teins (Figs. 2A and 2B). A similar finding was observed in
HT1080 and HepG2 cells. The GAF–DNA complex for-
Mock transfectants (a, b, and c), stable transfectants expressing core
HeLa cells expressing unrelated CD4 protein as an additional control
U/ml (b, e, h, and k) or 500 U/ml IFNa (c, f, i, and j) for 30 min at room
A second antibody, goat anti-mouse Ig, conjugated to fluorescein
ited a strong and distinct nuclear immunofluorescence in control HeLa
V proteins displayed a weak Stat1 expression, predominantly localized
ated control and HCV gene transfected cells.a cells.
i), and
g 1000
tat1-a.
exhibmation was ;fourfold higher in mock transfected
HT1080 control cell line than in cells transfected with
o382 BASU ET AL.FIG. 2. Inhibition of GAF–DNA complex formation by HCV protein(s) in IFNg-treated cells. Mock transfected control or experimental cells (as marked
n top) were either treated with IFNg (500 U/ml for 90 min) or left untreated. Nuclear extracts from cells were examined for GAF–DNA complex
formation by a gel retardation assay with a probe corresponding to the GAS element of the IRF-1 gene (a, c, and e). The addition of an antibody to
Stat1 in the nuclear extract–DNA reaction mixture inhibited GAF–DNA complex formation. The amount of complex formation was quantitated by
densitometric scanning and presented as a bar diagram (b, d, and f).
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383HCV CORE PROTEIN AND ISGF3/GAF MODULATIONHCV core or HCV1–2962 plasmid DNA (Figs. 2C and 2D).
Similarly, an increased GAF–DNA complex formation
(;twofold) was observed in mock transfected HepG2
cells as compared to HepG2 cells transfected with core
or HCV1–2962-expressing plasmid (Figs. 2E and 2F). Fur-
her analysis with an antibody to Stat1 verified inhibition
f GAF–DNA complex formation in both HT1080 and
epG2 cells and identified Stat1 as a component of the
omplex.
ISGF3–DNA complex formation was also analyzed us-
ng ISRE as a probe in IFNa-treated control and core-
FIG. 3. Inhibition of ISGF3–DNA complex formation by HCV protein
marked on top) were treated with IFNa (1000 U/ml for 90 min) or left un
ormation by gel retardation assay with a probe corresponding to the IS
n the nuclear extract–DNA reaction mixture inhibited ISGF3–DNA c
ensitometric scanning and presented as fold difference of the ISGF3expressing HeLa cells (Fig. 3A). The mobility and spec-
ificity of the ISGF3–DNA complex was verified using
l
IStat-specific antibodies which competed with the pro-
tein–DNA complex formation. The ISGF3–DNA complex
was ;threefold higher in mock transfected HeLa control
as compared to core or HCV1–2962-transfected HeLa cells
Fig. 3B). A similar result of ;threefold higher ISGF3–
NA complex formation was observed in the control over
ore-transfected HT1080 cells (Figs. 3C and 3D) and in
epG2 cells (data not shown). The gel shift assays for
AF and ISGF3 DNA complex formation were reproduc-
ble from at least three different experiments. Together,
ur results indicated that the HCV core protein modu-
Na-treated cells. Mock transfected control or experimental cells (as
. Nuclear extracts from cells were examined for ISGF3–DNA complex
ment of the 561 gene (a and c). Addition of antibodies to Stat1 or Stat2
x formation. The amount of complex formation was quantitated by
omplex in different cell lines (b and d).(s) in IF
treated
RE ele
ompleates both GAF and ISGF3 protein complex formation in
FN-treated cells.
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384 BASU ET AL.Effect of IFN on expression of the signaling proteins
Our results indicated that HCV core-protein expres-
sion lowers the level of GAF and ISGF3 in IFN-treated
cells. Thus, we investigated the protein expression level
of Stat1 and p48 in control and core-expressing HeLa
cell lysates by Western blot analysis using specific anti-
bodies. Results suggested an approximately threefold
decrease in Stat1 protein expression in core-expressing
HeLa cells than mock transfected control cells (Fig. 4A).
However, the level of p48 remained similar in both the
experimental and the control cells (Fig. 4C).
The phosphorylated Stat1 level was also investigated
in IFNa-treated control and experimental HeLa cells by
mmunoprecipitation. Cell lysates were immunoprecipi-
ated by a Stat1 monoclonal antibody and subjected to
estern blot analysis using an antibody directed to the
hosphotyrosine of Stat1 (Fig. 4B). The phosphorylated
orm of the Stat1 protein was barely detectable in core-
xpressing HeLa cells and could be due to lower Stat1
xpression in HeLa cells. In contrast, phosphorylated
tat1-a polypeptide was clearly visible in mock trans-
ected HeLa cells. A relatively lower level of Stat1 protein
xpression was also observed in HCV core-transfected
T1080 (Fig. 4E) and HepG2 cell lysates (Fig. 4H). On the
ther hand, expression level of the DNA binding protein
48 was similar in both cell lines (Figs. 4F and 4I).
ellular actin was used as an internal control for com-
arison (Figs. 4D, 4G, and 4J). Further examination of
FIG. 4. Effect of core protein on Stat1 and p48 expression in IFNa-tre
anes) cells were treated with 1000 U/ml IFNa for 30 min. HeLa ce
mmunoprecipitates were separated by SDS–8% PAGE and transferred
onjugated with horseradish peroxidase. Phosphorylated tyrosine moie
tat1-a/b and p48 were analyzed by Western blot using a monoclonal
An antibody to cellular actin was used as an internal control (d, g, and j)
sizes correlated with the migration of standard molecular weight marktat1 mRNA expression by RNase protection assay sug-
ested that the level of Stat1 increases greater thanwofold following IFNa treatment in mock transfected
HeLa cells than HCV core-expressing cells (Fig. 5). Sim-
ilar observations were made from cells treated with IFNg
(data not shown). All of the experiments presented in
Figs. 4 and 5 are representative of at least three inde-
pendent experiments exhibiting similar results. These
results suggested that HCV core protein modulates Stat1
expression at the transcriptional level. Thus, the core
protein appears to modulate the Jak/Stat pathways by
lowering the abundance of Stat1 protein.
HCV protein(s) does not inhibit induction of IFN
stimulated genes
ISRE-mediated signaling was examined from the level
of gene induction of two alternative IFN signaling path-
ways. IRF-1 mRNA is induced by IFNg with GAS as a cis
element and GAF as the transcription factors. On the
other hand, 561 mRNA is induced by IFNa using ISRE as
cis element and ISGF3 as cognate transcription factor.
ellular levels of the IFNg-inducible IRF-1 mRNA and
IFNa-inducible 561 mRNA were analyzed by RNase pro-
ection assay. Activation of the IRF-1 mRNA upon IFN
reatment (500 U/ml) was observed at a similar level for
t least up to 12 h in both mock transfected and core or
CV protein expressing HeLa cells (Figs. 6A and 6B),
nd a similar result was observed using a lower dose
100 U/ml) of IFNg (data not shown). Activation of IRF-1
mRNA was also observed following IFNg treatment of
lls. Mock transfected control (left lanes) or core gene transfected (right
s were immunoprecipitated with a monoclonal antibody to Stat1-a.
rocellulose for probing with a monoclonal antibody to phosphotyrosine
Stat1-a were detected by chemiluminescence (b). Expression levels of
y to Stat1-a (a, e, and h) and a polyclonal antibody to p48 (c, f, and i).
s on the right indicate the respective polypeptides, and their molecular
bco BRL).ated ce
ll lysate
onto nit
ties of
antibodHepG2 cells (Figs. 6C and 6D). Investigation for 561 gene
induction suggested an increase in mRNA level within
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385HCV CORE PROTEIN AND ISGF3/GAF MODULATION6 h of IFNa treatment, which then decreased slightly
etween 6 and 12 h in HepG2 cells (Fig. 6E). The reason
or this decline of 561 mRNA is unclear at present.
ime-dependent activation of 561 was also observed in
eLa cells (data not shown). These results suggested
hat even a reduced level of GAF or ISGF3 complex is
ufficient to activate the interferon-stimulated down-
tream effector genes of Jak/Stat signaling pathways,
nd this effect appeared to be dependent upon IFN
timulation.
DISCUSSION
Results from this study indicate that expression of core
rotein alone or together with other HCV proteins mod-
lates the transacting factors GAF or ISGF3 of the IFN-
nduced Jak/Stat signaling pathway. This may be related
o a decreased abundance of the Stat1 protein and/or a
eak translocation of Stat1 to the cell nucleus. However,
hese modulatory effects do not interfere with IFN-in-
uced downstream activation of the IRF-1 and 561 gene
FIG. 5. Analysis for Stat1 mRNA expression in HeLa cells upon IFNa
treatment by RNase protection assay. The mRNA expression level of Stat1
and L32 (internal control) were determined in untreated (marked U on top)
or IFNa (1000 U/ml) treated cells for 6 or 12 h (a). The relative abundance
f the Stat1 mRNA level was estimated by densitometric scanning after
ormalization against L-32 and shown as bar diagram (b).xpression. We have used ectopic expression of HCV
rotein in this study as that will be more relevant to theature of chronic HCV infection, when IFNa treatment is
normally offered. Our results from expression of HCV
proteins agree in part with the reduced GAF or ISGF3
formation observed following inducible expression of the
entire HCV open reading frame in osteosarcoma cells
(Heim et al.,1999), although a difference in Stat1 expres-
sion level was observed in our study. This difference in
results could be attributed to inducible vs stable expres-
sion system and the nature of the cell lines used. Our
study also suggests a difference in expression level
based on the cell types used. However, our results indi-
cate that even a reduced level of GAF or ISGF3 complex
in IFN-treated cells is sufficient to activate IS genes,
IRF-1 and 561. Thus, we find evidence to suggest a role
for the HCV core protein in the inhibition or impairment of
the Stat1 expression, which can be augmented by IFN
treatment for induction of the downstream effector gene
of Jak/Stat pathway in HeLa, HT1080, or HepG2 cells.
IFNa regulates the function of cytokines, their recep-
tors, and other molecules of immune importance (Good-
bourn et al., 2000). A large number of genes are induced
by IFNa, but only a few of these gene products have
been associated with an intrinsic antiviral activity. Those
identified include the p68 protein kinase (PKR) and 29-
59-oligoadenylate synthetase (29-59-OAS), which are both
dependent upon double-stranded RNA for activity, cer-
tain MxA family proteins, and the most recently identified
promyelocyte leukemia protein (Goodbourn et al., 2000).
While IFN-treated cells are resistant to many different
viruses, individual overexpression of these intrinsically
antiviral proteins confers host resistance only against
some viruses. HCV E2 and NS5A proteins have been
implicated in IFN resistance through inhibition of PKR
(Gale et al., 1997, 1998; Taylor et al., 1999). Inhibitory
properties of HCV E2 glycoprotein may occur by mimick-
ing the autophosphorylation site via a pseudosubstrate
mechanism (Taylor et al., 2001). PKR inhibition by E2 or
NS5A protein may contribute but do not solely explain
the resistance to sustained IFN treatment (Polyak et al.,
2000; Francois et al., 2000; Gerotto et al., 2000). In
chronic HCV patients, the expression of 29-59-OAS and
MxA are not significantly different at the hepatic mRNA
level when compared with chronic HBV or other liver
diseases of different etiology (Yu et al., 2000). HCV core
protein also activates 29-59-OAS gene in hepatocyte cell
lines, which is further enhanced upon treatment with
interferon (Naganuma et al., 2000). Unfortunately, the
lack of a suitable virus-cell culture system for study of
HCV growth does not allow the study the contribution of
IFN induced proteins for antiviral response at this time.
The function of Stat1 is to regulate a set of genes that
collectively provide innate immunity (Ihle, 1996). The ho-
mozygous mutant cells and animals devoid of functional
Stat1 protein revealed that Stat1 is indispensable for the
IFN pathway, but may not be necessary for other signal-
ing systems for normal development (Durbin et al., 1996).
d
t
from a
H
386 BASU ET AL.However, mutant animals demonstrated the essential
nature of Stat1-dependent system for survival in the face
of otherwise innocuous viral pathogens. This may result
from the combined loss of both type I and type II IFN
responses, which has been shown to impair some anti-
viral responses (van den Broek et al., 1995). Stat1-depen-
FIG. 6. Analysis for IFN-induced IRF-1 and 561 gene expression by
an internal control (a and c) were determined in IFNg (500 U/ml) trea
abundance of IRF-1 mRNA level (b and d) at 6 and 12 h of IFN trea
normalized with respect to actin used as an internal control. The results
epG2 cells for 6 and 12 h are also shown (e).ent innate immunity, presumably produced in response
o IFN, appears to be a crucial host defense mechanismcombating mouse hepatitis virus (MHV) disease. A ma-
jority of humans fail to develop protection against HCV
infection and Stat1 modulation by core protein may con-
tribute to this defect.
Although Stats are translocated to the nucleus after
activation, neither the mechanism underlying this trans-
protection assay. The mRNA expression level of IRF-1 and g-actin as
untreated (marked as U on top) HeLa and HepG2 cells. The relative
was estimated by densitometric scanning of the autoradiogram and
similar analysis for 561 mRNA expression in IFNa (1000 U/ml) -treatedRNase
ted or
tmentlocation nor the reason for their retention in the cyto-
plasm prior to stimulation is well understood (O’Shea,
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387HCV CORE PROTEIN AND ISGF3/GAF MODULATION1997). Two mechanisms, ubiquitination and dephosphor-
ylation, have been proposed for attenuating Stat activa-
tion. However, the relative importance of these two
mechanisms and the identity of the Stat phosphatase are
not known. A recent report suggests a complex of un-
phosphorylated Stat1 and IRF-1 transcribes the LMP2
gene, which would involve them in the processing of viral
and tumor antigens for presentation to CD81 T cells in
the context of MHC class I molecules (Chatterjee-
Kishore et al., 2000). IFNg is a potent inducer of MHC
class II expression and is activated through Jak/Stat
pathway. Regulation of MHC class II gene expression by
IFNg and other modulators occur primarily at the mRNA
ranscription, although posttranscriptional modulation
as been described. The results from our study are in
greement with the observations that HCV core protein
oes not disrupt the expression of MHC class II mole-
ules on cell surface (Hiasa et al., 1998; Large et al.,
999). Our data suggest that the core protein when con-
titutively expressed in cells decreases Stat1 expres-
ion, the level of which differs depending on the cell type
sed. However, this effect can be overcome by IFN
reatment to induce the downstream effector gene ex-
ression of the Jak/Stat signaling pathways. Stat1 also
lays an important role in growth arrest, in promoting
poptosis, and is implicated as a tumor suppressor
Bromberg and Darnell, 2000). Cross talk between Stat
nd other cellular signaling pathways can be achieved
y the action of certain Stat-associated proteins. For
xample, an interaction between ERK and Stat may con-
ect the MAPK and Stat signaling pathways (Shuai,
000). IFNg, which activates large amounts of Stat1,
decreases the AP1- and ETS-mediated transcriptional
increase, possibly by competing for CBP, p300, or both
(Darnell, 1997). Stats may have direct effects on inhibiting
proliferation by induction of cyclin-dependent kinase in-
hibitors, such as p21/Waf1 (Chin et al., 1996). This may
explain the antiproliferative effects of interferons. Inter-
estingly, a reduced level of p21/Waf1 protein expression
in HCV-related hepatocellular carcinoma has been re-
ported (Shi et al., 2000). Our present results coupled with
the previous observations made on the effect of HCV
core protein mediated modulation of AP-1, MAPKK, and
p21/Waf1 (Hayashi et al., 2000; Ray et al., 1998b; Shriv-
astava et al., 1998; Tsuchihara et al., 1999) suggest that
core protein may target a number of cellular genes that
could have a concerted action on normal cell growth
checkpoint control. HCV has a uniquely adapted mech-
anism to inhibit host antiviral effector pathways, ensuring
survival in the human host. Studies on expression of
some of IFN-regulated genes in the liver of chronic HCV
patients (Meier et al., 2000; Patzwahl et al., 2001; Yu et al.,
2000) does not suggest a clear picture for their contribu-
tion in anti-HCV response. A complex gene network is
involved in the regulation of the IFN system. In fact, the
59 regulatory region of the IRF-1 gene has been shown tocontain highly GC-rich sequences and consensus bind-
ing sequences for several known transcription factors,
including NF-kB (Harada et al.,1994). However, our ob-
servations do not support such an alternative effect,
especially when results from IFNa and IFNg are consid-
red, since both of these pathways are partially overlap-
ing through Stat1. Even though our results suggest that
FN-stimulated genes of the Jak/Stat pathway are not
mpaired or blocked by HCV proteins, the relative weak-
ess of IFNa therapy may arise from virus-mediated
interruption of other gene products with antiviral activity
or from the nature of poor antiviral activity associated
with human hepatocytes.
MATERIALS AND METHODS
Cell lines, plasmid construct, and protein expression
Human cervical carcinoma (HeLa) and human hepa-
toma (HepG2) cells were obtained from the American
Type Culture Collection (Rockville, MD). The human fi-
brosarcoma epithelial-like HT1080 cells were kindly pro-
vided by G. R. Stark (Cleveland Clinic Foundation, OH).
Cells were grown in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% heat-inactivated
fetal bovine serum. A full-length HCV clone (kindly pro-
vided by C. M. Rice, Washington University, St. Louis,
MO) was digested with suitable restriction enzymes and
the genomic region representing the structural and non-
structural proteins (amino acids 1–2962) was subcloned
into a pCIneo mammalian expression vector, introducing
a stop codon at the translational end. Cloning of the HCV
genomic region representing the core protein (amino
acids 1–191) has been described earlier (Ray et al., 1995).
Subconfluent cell monolayers were transfected with a
mammalian expression vector containing HCV (pCIneo/
HCV1–2962) or HCV core (pcDNA3/Core1–191) gene using
lipofectamine (Gibco BRL, MD). An empty vector DNA
was transfected into cells for use as a control. Neomy-
cin-resistant stable transfectants were pooled to avoid
clonal selection and tested for integration of HCV gene
and protein expression. Stable cell transfectants exhib-
ited NS5A and/or core protein expression (depending on
the plasmid transfected) separately by Western blot anal-
ysis and indirect immunofluorescence (Ray et al., 1996b)
sing monoclonal antibodies (mAbs) to NS5A protein
Biogenesis, Inc., MA) or core protein (C7-50, kindly pro-
ided by Jack R. Wands, Harvard Medical School, MA).
dditionally, cells transfected with the pCIneo/HCV1–2962
gene exhibited distinct immunofluorescence with mono-
clonal antibody to E1 or E2. Transfected cells did not
exhibit unusual growth characteristics and were ana-
lyzed for the role of viral protein(s) in IFN signaling
pathways.
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Stable cell transfectants were examined for subcellu-
lar localization of Stat 1 expression by a specific mAb
(Santa Cruz Biotechnology, CA). Briefly, cells grown over-
night on coverslips were left untreated or treated with
IFNg (500 U/ml) or IFNa (1000 U/ml) for 30 min. Cells
were washed and then fixed with methanol/acetone (1:1)
for 2 min. After washing, cells were incubated with the
mAb at room temperature for 1 h, washed, and stained
with a goat anti-mouse IgG conjugated to fluorescein
isothiocyanate. A human CD4 gene stably transfected
into HeLa cells was also included as an unrelated con-
trol in similar immunofluorescence study.
Immunoprecipitation and Western blot analysis
Cells were treated with 1000 U/ml IFNa or 500 U/ml of
IFNg for 90 min, washed, and lysed in 13 lysis buffer
(0.5% NP-40, 50 mM Tris–HCl, pH 8.0, 10% glycerol,
0.1mM EDTA, 300 mM NaCl, 1mM DTT, and a cocktail of
protease inhibitors) for 1 h on ice. Cell lysates were
incubated with a monoclonal antibody to Stat1-a at 4°C
and the immunoprecipitate was immobilized onto protein
A–Sepharose CL-4B (Pharmacia, NJ). The sample was
subjected to electrophoresis on a SDS–polyacrylamide
gel. Proteins were transferred onto a nitrocellulose mem-
brane and blocked with 5% low-fat milk. HRP-conjugated
anti-human phosphotyrosine monoclonal antibody
(Santa Cruz Biotechnology) was used for detection of the
phosphorylated form of the Stat1 polypeptide. Stat1 and
p48 protein expression was also determined directly
from cell lysates by Western blot analysis using specific
monoclonal and polyclonal antibodies, respectively
(Santa Cruz Biotechnology). An antibody to cellular actin
(Oncogene Research, CA) was used as a control in
Western blot for analyzing protein load in each lane. A
HRP-conjugated second antibody to mouse Ig was used
to visualize the protein bands by enhanced chemilumi-
nescence (ECL; Amersham, IL).
Gel retardation assay
The gel retardation assay for GAF and ISGF3 was
performed as previously described (Leonard and Sen,
1996). Briefly, cells were treated for 30 min with1000 U/ml
of IFNa or 500 U/ml of IFNg and untreated cells were
used as control. Cells were lysed with NP-40 in low-salt
buffer (10mM HEPES, pH 7.9; 10 mM KCl, 0.1 mM EDTA,
1 mM DTT, 0.5mM PMSF, and a cocktail of protease
inhibitors) on ice for 5 min. The nuclear pellet was col-
lected by centrifugation and suspended in a high-salt
buffer (20 mM HEPES, pH 7.9; 0.4 mM NaCl, 0.1 mM
EDTA, 1 mM DTT, and 1 mM PMSF) for 30 min at 4°C.
Nuclear extracts were obtained by centrifugation at
12,000 g, and aliquots were flash frozen immediately for
storage at 270°C. The protein concentration of the nu-
b
pclear extracts were determined using protein assay re-
agent (Bio-Rad, CA). The GAS element located between
2129 and 2106 of the IFNg-inducible IRF1 gene, and
ISRE element located between 2125 and 293 of the
IFNa 561 gene (Leonard and Sen, 1997), were used as
probes (kindly provided by G. C. Sen, Cleveland Clinic
Foundation, OH) for our studies. The annealed double-
stranded probes were end labeled with [a-32P]dCTP us-
ing a DNA polymerase to fill in the ends. Gel retardation
assay was initially standardized by varying the quantity
of the nuclear extracts in obtaining a linear range of
detection of the specific complexes. Finally, 10 mg of
nuclear proteins were incubated with 32P-labeled oligo-
ucleotide probe in the presence of poly[d(I-C)] in a
inding buffer (50 mM HEPES, pH 7.5; 250 mM NaCl, 2.5
M EDTA, 1mM MgCl2, 2.5 mM DTT, and 1 mM PMSF, 5
M MgCl2, 20% glycerol, and a cocktail of protease
inhibitors) for 30 min at room temperature. The specificity
of the Stat1 protein in DNA–protein complex was identi-
fied by adding a murine monoclonal antibody to Stat1
(Santa Cruz) to the reaction mixture before formation of
the complex. A rabbit polyclonal antibody to Stat2 (Santa
Cruz), unrelated murine monoclonal antibodies, or fetal
calf serum as negative controls, were used separately
for determining the inhibitory effect on DNA–protein
complex formation. The samples were electrophoresed
until the free radiolabeled probe was removed from the
nondenaturing 5% polyacrylamide separation gel and
exposed to X-ray film for autoradiography. The autoradio-
gram was scanned densitometrically for a comparison of
band intensity.
RNase protection assay
The induction of Stat1, IRF-1, and 561mRNAs were
analyzed using specific probes as described earlier (Kal-
vakolanu et al., 1991; Leonard and Sen, 1997). A 409-
nucleotide fragment of the Stat1 gene (Pharmingen, CA),
a 175-nucleotide fragment (nucleotide positions
192–367) of the IRF-1 gene, or 142-nucleotide fragment
(nucleotide positions 1369–1511) of the 561 gene (kindly
provided by G. C. Sen) was used as a probe. A 113-
nucleotide-long L32 and 128-nucleotide-long g-actin
probe was used for internal control. Briefly, total RNA
was isolated from cells, with or without IFN treatment,
using a RNA isolation kit (Gentra Systems, MN). An
antisense RNA probe was labeled with [32P]UTP and cold
NTPs using SP6 or T7 RNA polymerase. The probe was
hybridized in excess to target cellular RNA (2 mg) over-
ight. Free probe and single-stranded RNA were di-
ested with RNAseA and RNAseT1, followed by protein-
se K treatment. The protected RNA was recovered by
henol/chloroform extraction, ethanol precipitation, and
dentified by resolving on a 5% urea–polyacrylamide gel
y electrophoresis, followed by autoradiography. The
rotected RNA band in the autoradiogram was densito-
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ization against the L32 or g-actin as an internal control.
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